Verastem, Inc. Form 8-K Summary
Business Context and Reporting Period
Verastem, Inc. (VSTM) filed a Current Report on Form 8-K dated August 6, 2026. The filing details the entry into Amendment No. 3 to a Note Purchase Agreement originally dated January 13, 2025, with funds managed by Oberland Capital Management LLC. The amendment restructures the company's debt financing related to its primary products, avutometinib and defactinib.
Key Financial Metrics and Debt Structure
The filing does not provide specific revenue, profit, or cash flow figures for the reporting period. However, it outlines significant changes to the company's debt obligations:
- Initial Notes: Existing notes with an aggregate principal amount of $75.0 million. Interest is variable (Term SOFR + 4.29% + 3.71%, capped at 9.75%). Up to 50% of interest may be paid-in-kind for the first eight payment dates.
- Revenue Notes (New Series): A new series of notes with an aggregate purchase price of up to $75.0 million, replacing previous conditional tranches.
- Tranche 1 (Second Purchase): $50.0 million to be issued on August 28, 2026, subject to conditions.
- Tranche 2 (Third Purchase): Optional $25.0 million available by May 15, 2027, contingent on worldwide net sales of avutometinib and defactinib reaching at least $40.0 million in the preceding calendar quarter.
- Revenue Payments: Instead of fixed interest, Revenue Notes require quarterly payments equal to 4.50% of net sales of the combined products. This rate drops to 1.75% after December 31, 2031, if total payments equal or exceed 100% of the funded amount.
- Repayment Caps: Early redemption requires a "Repayment Amount" ranging from 135% to 185% of the funded amount, depending on timing and triggering events (e.g., change of control, IP sale).
Material Changes Versus Prior Period
The primary material change is the restructuring of the debt instrument from a traditional fixed-interest tranche structure to a revenue-based financing model for the new notes:
- Debt Restructuring: The previous conditional second and third tranches of Initial Notes were replaced by the new "Revenue Notes" series.
- Interest Mechanism: The new Revenue Notes do not bear fixed interest; instead, they utilize a revenue-sharing mechanism tied to product sales.
- Initial Notes Adjustment: The "Revenue Participation Percentage" for the existing Initial Notes was fixed at 1.00% and will not be adjusted by the issuance of the new Revenue Notes.
- Covenants: The agreement contains no financial covenants but maintains customary affirmative and negative covenants, including limitations on dividends, stock repurchases, and additional debt.
Guidance, Outlook, and Risks
Outlook and Conditions: The ability to access the optional $25.0 million tranche of Revenue Notes is explicitly tied to a sales milestone of $40.0 million in a single calendar quarter for the company's primary products.
Risks and Contingencies:
- Make-Whole Payment: If the company fails to pay 100% of the funded amount via revenue payments by December 31, 2031, it must make a one-time contingent make-whole payment for the shortfall.
- Collateral: Obligations are secured by a first-priority security interest on substantially all assets, including intellectual property related to avutometinib and defactinib.
- Default Penalties: In the event of default, the interest rate on Initial Notes may increase by an additional 5.00%.
- Equity Dilution Risk: In specific voluntary prepayment scenarios (e.g., sale of IP), up to 25% of the repayment amount may be paid in common stock.
Investor Verification Checklist
- Verify the company's current quarterly net sales of avutometinib and defactinib to assess the likelihood of triggering the optional $25.0 million tranche.
- Review the full text of Amendment No. 3 (Exhibit 10.1) to understand specific "customary conditions precedent" for the August 28, 2026, issuance.
- Monitor the "Test Date Condition" status as of December 31, 2031, to determine if the revenue payment rate will decrease or if a make-whole payment will be required.
- Assess the impact of the 1.00% revenue participation cap on the Initial Notes versus the 4.50% rate on Revenue Notes on future cash flow projections.
- Confirm the status of the company's intellectual property portfolio, as it serves as primary collateral for the entire debt facility.